IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma (NCT05987332)

🧪 Interventions in This Study

• IDE196 (DRUG)
• Crizotinib (DRUG)
• Pembrolizumab (DRUG)
• Ipilimumab (DRUG)
• Nivolumab (DRUG)
• Dacarbazine (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (68 Sites)

Showing the first 25 of 68 sites.

• Honor Health — Scottsdale, Arizona
• Moores Cancer Center — La Jolla, California
• UCLA Medical Center — Los Angeles, California
• The Angeles Clinic and Research Institute — Los Angeles, California
• California Pacific Medical Center (CPMC) — San Francisco, California
• University of California San Francisco — San Francisco, California
• University of Colorado Cancer Center — Aurora, Colorado
• SCRI at HealthONE — Denver, Colorado
• University of Miami Sylvester Comprehensive Cancer Center — Miami, Florida
• Moffitt Cancer Center — Tampa, Florida
• Northside Hospital Atlanta — Atlanta, Georgia
• University of Iowa — Iowa City, Iowa
• Massachusetts General Hospital — Boston, Massachusetts
• Dana Farber Cancer Institute — Boston, Massachusetts
• The Cancer and Hematology Centers — Grand Rapids, Michigan
• Minnesota Oncology Hematology, P.A. — Burnsville, Minnesota
• Mayo Clinic — Rochester, Minnesota
• Washington University School of Medicine — St Louis, Missouri
• Roswell Park Cancer Institute — Buffalo, New York
• Northwell Health — Manhasset, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• Duke University Health System — Durham, North Carolina
• University of Cincinnati — Cincinnati, Ohio
• The Cleveland Clinic Foundation — Cleveland, Ohio
• Thomas Jefferson University — Philadelphia, Pennsylvania

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic Uveal Melanoma

• Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma — Tampa, Florida
• Vorinostat in Treating Patients With Metastatic Melanoma of the Eye — New York, New York
• A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas — Boston, Massachusetts
• Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions — Los Angeles, California
• Tebentafusp-tebn With LDT in Metastatic UM — Philadelphia, Pennsylvania

Explore by condition: All Metastatic Uveal Melanoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.